亚太地区人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型（颗粒佐剂、乳剂佐剂、组合佐剂及其他）、应用（流感、肝炎、人乳头瘤病毒 (HPV) 及其他）和最终用户（制药和生物技术公司、CMO 和 CRO 及其他）划分

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 113    |    Report Code: BMIRE00030361    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Human Vaccine Adjuvants Market
Free Sample Buy Now
2022 年亚太地区人用疫苗佐剂市场价值为 3.3019 亿美元，预计到 2030 年将达到 10.0852 亿美元；预计 2022 年至 2030 年的复合年增长率为 15.0%。

不断增长的制药业推动亚太地区人用疫苗佐剂市场发展

不断扩张的制药业预计将对佐剂的需求产生积极影响，因为它们可以提高疫苗的有效性和安全性。制药行业对传染病、癌症和自身免疫性疾病的日益关注为开发针对这些特定疾病领域的个性化疫苗和佐剂提供了平台。这为佐剂制造商提供了一个机会，可以开发专门的佐剂来增强对这些疾病疫苗的免疫反应。根据 EFPIA 的数据，2016-2021 年期间，巴西、中国和印度制药业分别增长了 11.7%、6.7% 和 11.8%，而欧盟五大市场和美国市场的平均市场增长率分别为 5.8% 和 5.6%。此外，根据印度品牌资产基金会 (IBEF) 的数据，印度是全球制药业的主要新兴参与者。该国是世界上最大的仿制药贸易国，占全球供应量的近 20%。它供应着全球疫苗需求的约 50%。国内制药业包括 3,000 家制药公司和约 10,500 个制造单位。根据印度政府的官方数据，印度制药业的价值接近 500 亿美元，其中超过 250 亿美元来自出口。印度占全球仿制药出口的约 20%。此外，日本是世界上最大的医药市场之一。根据厚生劳动省 (MHLW) 的年度医药生产统计，2020 年日本处方药和非处方药市场规模为 1070 亿美元。随着行业不断发展和创新，对可支持个性化疫苗开发的佐剂的需求不断增加，推动了亚太地区人用疫苗佐剂市场的显着增长和投资。因此，全球不断发展的制药业可能会在未来几年为亚太地区人用疫苗佐剂市场创造丰厚的增长机会。

亚太地区人用疫苗佐剂市场概况

中国已在医疗保健和制药行业投入巨资，旨在增强国内生产、研发能力。这一战略重点使该国成为亚太地区人用疫苗佐剂市场的关键参与者。此外，中国是世界上人口最稠密的国家之一；目前人口约为 14.1 亿。根据 2020 年 10 月发布的最新全球疾病负担 (GBD) 研究，中国人口易患各种传染病、慢性病和急性病。

传染病患病率的上升预计将推动对疫苗接种的需求。根据 ICO/IARC 2023 年 HPV 和癌症信息中心的报告，中国有 5.824 亿 15 岁及以上的女性面临患 HPV 相关宫颈癌的风险。据估计，中国普通人群中约有 3.8% 的女性在特定时间内感染宫颈 HPV-16/18，69.1% 的浸润性宫颈癌归因于 HPV 16 或 18。因此，患者数量的增加和对治疗疫苗的需求增加也有望推动亚太地区人用疫苗佐剂市场的增长。

亚太地区人类疫苗佐剂市场收入及预测至 2030 年（百万美元）

亚太地区人类疫苗佐剂市场细分

亚太地区人类疫苗佐剂市场分为类型、应用、最终用户和国家。

根据类型，亚太地区人类疫苗佐剂市场分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据最大市场份额。

就应用而言，亚太地区人类疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 和其他。流感细分市场在 2022 年占据了最大的市场份额。

按最终用户划分，亚太地区人用疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司细分市场在 2022 年占据了最大的市场份额。

按国家划分，亚太地区人用疫苗佐剂市场细分为日本、中国、印度、澳大利亚、韩国和亚太地区其他地区。2022 年，中国占据了亚太地区人用疫苗佐剂市场份额的主导地位。

Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Hawaii Biotech Inc、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是亚太地区人用疫苗佐剂市场的一些领先公司。

Asia Pacific Human Vaccine Adjuvants Strategic Insights

Strategic insights for Asia Pacific Human Vaccine Adjuvants involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-human-vaccine-adjuvants-market-strategic-framework.webp
Get more information on this report

Asia Pacific Human Vaccine Adjuvants Report Scope

Report Attribute Details
Market size in 2022 US$ 330.19 Million
Market Size by 2030 US$ 1,008.52 Million
Global CAGR (2022 - 2030) 15.0%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 类型
  • 颗粒佐剂
  • 乳化佐剂
  • 组合佐剂
By 应用
  • 流感
  • 肝炎
  • 人乳头瘤病毒
By 最终用户
  • 制药和生物技术公司
  • CMO 和 CRO
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Croda International Plc
  • CSL Ltd
  • Dynavax Technologies Corp
  • Hawaii Biotech Inc
  • Novartis AG
  • Novavax Inc
  • Phibro Animal Health Corp
  • Seppic SA
  • SPI Pharma Inc
    		•
    Get more information on this report

    Asia Pacific Human Vaccine Adjuvants Regional Insights

    The regional scope of Asia Pacific Human Vaccine Adjuvants refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-human-vaccine-adjuvants-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - Asia Pacific Human Vaccine Adjuvants Market

    1. Croda International Plc 
    2. CSL Ltd 
    3. Dynavax Technologies Corp 
    4. Hawaii Biotech Inc 
    5. Novartis AG 
    6. Novavax Inc 
    7. Phibro Animal Health Corp 
    8. Seppic SA 
    9. SPI Pharma Inc 

    Frequently Asked Questions
    How big is the Asia Pacific Human Vaccine Adjuvants Market?

    The Asia Pacific Human Vaccine Adjuvants Market is valued at US$ 330.19 Million in 2022, it is projected to reach US$ 1,008.52 Million by 2030.

    What is the CAGR for Asia Pacific Human Vaccine Adjuvants Market by (2022 - 2030)?

    As per our report Asia Pacific Human Vaccine Adjuvants Market, the market size is valued at US$ 330.19 Million in 2022, projecting it to reach US$ 1,008.52 Million by 2030. This translates to a CAGR of approximately 15.0% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Human Vaccine Adjuvants Market report typically cover these key segments-

  • 类型 (颗粒佐剂, 乳化佐剂, 组合佐剂)
  • 应用 (流感, 肝炎, 人乳头瘤病毒)
  • 最终用户 (制药和生物技术公司, CMO 和 CRO)

    • What is the historic period, base year, and forecast period taken for Asia Pacific Human Vaccine Adjuvants Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Human Vaccine Adjuvants Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in Asia Pacific Human Vaccine Adjuvants Market?

    The Asia Pacific Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Croda International Plc
  • CSL Ltd
  • Dynavax Technologies Corp
  • Hawaii Biotech Inc
  • Novartis AG
  • Novavax Inc
  • Phibro Animal Health Corp
  • Seppic SA
  • SPI Pharma Inc
    • Who should buy this report?

    The Asia Pacific Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.

    asia-pacific-human-vaccine-adjuvants-market